Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 217-316-1 | CAS number: 1809-19-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- chronic toxicity: inhalation
- Type of information:
- other: read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with national standard methods with acceptable restrictions
- Justification for type of information:
- Justification for Read Across is provided in Section 13 of IUCLID
Data source
Referenceopen allclose all
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 987
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 997
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 453 (Combined Chronic Toxicity / Carcinogenicity Studies)
- Deviations:
- yes
- Remarks:
- limited documentation
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Source Chemical 07
- IUPAC Name:
- Source Chemical 07
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Fischer 344/DuCrj
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Japan Inc.
- Housing: The animals were housed individually in wire-mash cages attached to the inhalation chamber.
- Diet (e.g. ad libitum): solid chow for rats (CRF-1, Charles River Japan Inc.)
- Water (e.g. ad libitum): filtered and sterilised tap water
- Acclimation period: 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2 °C
- Humidity (%): 55 ± 15 %
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Vehicle:
- not specified
- Remarks on MMAD:
- MMAD / GSD: not applicable
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Hazleton 1000 Inhalation Exposure Chamber - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analytical control of chamber concentration: analytical values close to nominal ones.
- Duration of treatment / exposure:
- 12 months (total exposure time: males: 7318-7341 hours; females: 7474 - 7496 hours)
- Frequency of treatment:
- continuously, average about 20 h/d
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0.013 mg/L air (nominal)
- Remarks:
- corresponding to 10 ppm
- Dose / conc.:
- 0.13 mg/L air (nominal)
- Remarks:
- corresponding to 100 ppm
- Dose / conc.:
- 1.3 mg/L air (nominal)
- Remarks:
- corresponding to 1000 ppm
- No. of animals per sex per dose:
- 20
- Control animals:
- yes
Examinations
- Observations and examinations performed and frequency:
- - CAGE SIDE OBSERVATIONS: Yes
- DETAILED CLINICAL OBSERVATIONS: Yes
- BODY WEIGHT: Yes
- FOOD CONSUMPTION: the feed to be consumed during a week was determined for two animals, and the daily food consumption per animal was then calculated. The calculation was done weekly during the first 13 weeks of exposure, and monthly thereafter.
- HAEMATOLOGY: Yes
- CLINICAL CHEMISTRY: Yes
- URINALYSIS: Yes - Sacrifice and pathology:
- - GROSS PATHOLOGY: Yes
- HISTOPATHOLOGY: Yes - Statistics:
- All the data obtained were analysed by t-test, Fischer´s exact test or Armitage´s chi-square test as appropriate for any significant difference.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One female rat of the 1.3 mg/L dose group and one male rat of the 0.013 mg/L dose group died or were sacrificed in extremis (on day 337 and on day 340, respectively). This was considered spontaneous on the basis of the absence of a consistent dose relationship.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- A very slight transient suppression of body-weight gain was observed for males and females of the 1.3 mg/L dose group from week 27 through 44 (less than 5 %). This has to be attributed to temporary occurrence of slight diarrhea in these groups during this period. The otherwise addressed significant decreases in body weight at the end of the study are not noticable representing the time-course of body weight development.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- The high-dose males showed a minimal, but significant decrease in food consumption from week 30 to the end. However, this was not more than about 5 % of the control.
- Food efficiency:
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Hematologic examinations revealed no clear changes which could be attributed to exposure.
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Serum biochemical examination showed a small tendency to decrease for alkaline phosphatase, the enzymatic activities of GOT, GPT, LDH and gamma-GTP did not show any differences. Free fatty acid showed lower values in all exposure groups without dose-response relationship. Cholesterol and triglyceride remained unchanged. Changes of other clinical-chemical parameters showed no correlation with exposure.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- Urinalysis showed no changes suggesting effects from exposure.
- Behaviour (functional findings):
- not examined
- Immunological findings:
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Data of the organ/body weight ratio revealed a dose-related upward tendency in the liver and spleen for females which remained within a 5 % range.
- Gross pathological findings:
- not examined
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Histopathological examinations showed a variety of non-tumoral changes in various organs, many of them were infrequent findings which were possibly accidental. Except for swelling of chromophobic cells of the pituitary, there was no findings which could be related to exposure level.
- Histopathological findings: neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- For tumoral changes, similarly, almost all the findings observed were considered spontaneous due to aging.
- Details on results:
- According to the authors, only in the 1.3 mg/L dose-group changes could be considered treatment-related. But based on the minor degree and severity, these changes have no pathological meaning and may be considered as toxicologically irrelevant.
Levels of 0.13 mg/L or less (at 20 h/d for 2 years) did not produce any effect (= NOEC). 1.3 mg/L is adopted as LOAEC, although it may be considered as a NOAEC.
Effect levels
open allclose all
- Dose descriptor:
- NOEC
- Effect level:
- 0.13 mg/L air (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
- Dose descriptor:
- LOAEC
- Effect level:
- 1.3 mg/L air (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- NOEC (chronic, rat) = 0.13 mg/L air (corresponding to 100 ppm)
- Executive summary:
The chronic toxicity of the substance via inhalation was evaluated in an experimental study conducted in a manner which was equivalent to the OECD Guideline 453, in a Combined Chronic Toxicity and Carcinogenicity study. Groups of 20 male and 20 female Fischer 344/DuCrj rats were exposed to test item concentrations of 10, 100 and 1000 ppm (corresponding to 0.013, 0.13 and 1.3 mg/L air) continuously (ca. 20 hours per day) for 12 months (males: 7318-7341 hours; females: 7474 - 7496 hours) via inhalation chambers. Negative control animals were tested in parallel.
No mortality during the study period was associated with toxicity due to the absence of a dose-depended relationship: one high-dose and one low-dose animal was eiher sacrificed in extremis or found dead. Very slight (less than 5 % difference from controls), transient suppression of body weight gain was observed among high-dose males and females between weeks 27 and 44, which was attributed to the temporary occurrence of slight diarrhea. High-dose males demonstrated a minimal, but significant, decrease in food consumption from week 30 to end of study; however this differed by less than 5 % from the controls. A dose-related increase in the ratio between liver and spleen weights and body weight was observed among female animals, but this difference was less than 5 %. Swelling of the chromophobic cells of the pituitary was also observed.
According to the authors, only the observations of the 1.3 mg/L dose group could be considered treatment-related. Based on the minor degree and severity (less than 5 % from control values), these changes have no pathological meaning and it cannot be excluded that these findings are toxicologically irrelevant. Levels of 0.13 mg/L or less did not produce any effect (NOEC), therefore, 1.3 mg/L is adopted as LOAEC, although it may be considered as a NOAEC.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.